The American Heart Association’s 2008 Statement of Principles for Healthcare Reform

Gibbons, Raymond J.; Jones, Daniel W.; Gardner, Timothy J.; Goldstein, Larry B.; Moller, James H.; Yancy, Clyde W.

doi:10.1161/circulationaha.108.191092

Cited by 51 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In its "Statement of Principles for Healthcare Reform" 103 published in Circulation in the fall of 2008, the AHA/ASA recognized that national health reform was critical to reducing death and disability attributable to cardiovascular disease. The 6 principles elucidated in the statement (access to affordable healthcare coverage, preventive benefits and incentives built into the healthcare system, promotion of high-quality care, reduction of disparities in care, support for research, and growth and diversification of the healthcare workforce) provide a useful framework for examining the potential impact that aspects of the law may or may not have on stroke mortality, incidence, and cost.…”

Section: Healthcare Reformmentioning

confidence: 99%

Forecasting the Future of Stroke in the United States

Ovbiagele¹,

Goldstein²,

Higashida³

et al. 2013

Stroke

Self Cite

694

365

View full text Add to dashboard Cite

Background and Purpose-Stroke is a leading cause of disability, cognitive impairment, and death in the United States and accounts for 1.7% of national health expenditures. Because the population is aging and the risk of stroke more than doubles for each successive decade after the age of 55 years, these costs are anticipated to rise dramatically. The objective of this report was to project future annual costs of care for stroke from 2012 to 2030 and discuss potential cost reduction strategies. Methods and Results-The American Heart Association/American Stroke Association developed methodology to project the future costs of stroke-related care. Estimates excluded costs associated with other cardiovascular diseases (hypertension, coronary heart disease, and congestive heart failure). By 2030, 3.88% of the US population >18 years of age is projected to have had a stroke. Between 2012 and 2030, real (2010$) total direct annual stroke-related medical costs are expected to increase from $71.55 billion to $184.13 billion. Real indirect annual costs (attributable to lost productivity) are projected to rise from $33.65 billion to $56.54 billion over the same period. Overall, total annual costs of stroke are projected to increase to $240.67 billion by 2030, an increase of 129%. Conclusions-These projections suggest that the annual costs of stroke will increase substantially over the next 2 decades.Greater emphasis on implementing effective preventive, acute care, and rehabilitative services will have both medical and societal benefits. Key Words: AHA Scientific Statements ◼ burden of illness ◼ cost of illness ◼ early medical intervention ◼ epidemiology ◼ ethnicity ◼ healthcare reform ◼ projections and predictions ◼ race ◼ sex ◼ thrombolysis, therapeutic ◼ treatment

show abstract

Section: Healthcare Reformmentioning

confidence: 99%

Forecasting the Future of Stroke in the United States

Ovbiagele¹,

Goldstein²,

Higashida³

et al. 2013

Stroke

Self Cite

694

365

View full text Add to dashboard Cite

show abstract

“…Coronary artery disease (CAD) is the leading cause of morbidity and mortality in both developed and developing countries (1). Coronary atherosclerosis involves a prolonged asymptomatic developmental phase, with its clinical manifestations often resulting in angina pectoris, acute myocardial infarction or cardiac death.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of coronary computed tomography angiography versus exercise electrocardiography for coronary artery disease: a systematic review and meta-analysis

Yin¹,

Wang²,

Zheng³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Both coronary computed tomography angiography (CCTA) and exercise electrocardiography (ExECG) are non-invasive testing methods for the evaluation of coronary artery disease (CAD). However, there was controversy on the diagnostic performance of these methods due to the limited data in each single study. Therefore, we performed a meta-analysis to address these issues. Methods: We searched PubMed and Embase databases up to May 22, 2015. Two authors identified eligible studies, extracted data and accessed quality. Pooled estimation of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), summary receiver-operating characteristic curve (SROC) and the area under curve (AUC) of CCTA and ExECG for the diagnosis of CAD were calculated using Stata, Meta-Disc and Review Manager statistical software. and 0.7727±0.0638, respectively. There is no heterogeneity caused by threshold effect in CCTA or ExECG analysis. The Deeks' test showed no potential publication bias (P=0.17).Conclusions: CCTA has better diagnostic performance than ExECG in the evaluation of CAD, which can provide a better solution for the clinical problem of the diagnosis for CAD. J Thorac Dis 2016;8(7):1688-1696 jtd.amegroups.com standard for assessing anatomical stenosis severity, a variety of non-invasive testing methods have been advocated recently to provide an anatomic and/or functional evaluation of coronary artery. Available methods include exercise/stress electrocardiography (ExECG), single proton emission computed tomography (SPECT), myocardial perfusion imaging (MPI), coronary computed tomography angiography (CCTA) and coronary computed tomography with fractional flow reserve (FFRCT). Despite these facts, assessment of the presence of CAD remains challenging.Among these diagnostic methods, ExECG is a wellestablished and inexpensive procedure to evaluate intermediate risk patients with angina pectoris (2). However, ExECG has relatively limited diagnostic performance in patients with silent CAD (3). As a new non-invasive alternative test, CCTA has high diagnostic performance to rule out CAD (4,5). Moreover, CCTA can be used in patients with equivocal stress test or unable to exercise stress test (6). But this method also suffers a number of limitations, such as a progressive loss of sensitivity and specificity as the pretest probability of disease decreases (7).To date, several studies have compared the effectiveness of CCTA with that of ExECG for the diagnosis of CAD (8)(9)(10)(11)(12)(13)(14). But there was controversy about the specificity of two arms (12,13). Additionally, a major limitation of these investigations was their reliance, by necessity, on observational studies due to the limited data in each single study. Therefore, we performed a meta-analysis to compare the diagnostic performance of CCTA and ExECG for CAD based on a larger data, which indicates a more specific comparison about the value of anatomic and functional evaluation in clinical decisions. Methods ...

show abstract

“…In this way, access to new therapies, as well as established generics, is based on economic condition. The AHA consistently has advocated for equity and affordability, 39 and it is imperative that the association continue this work as the voice of patients and work toward ensuring equitable access for all.…”

Section: Aha Considerationsmentioning

confidence: 99%

American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics

Antman¹,

Creager²,

Houser³

et al. 2017

Circulation

View full text Add to dashboard Cite

Net US spending on pharmaceuticals reached $309.5 billion in 2015, an 8.5% increase from the year before, and is expected to reach between $370 and $400 billion by 2020. These current and projected levels have raised serious concerns by policy makers, providers, payers, and patient groups that they are unsustainable and threaten the affordability of and accessibility to much-needed therapies for patients. Two trends related to drugs/biologics and generic drugs/biosimilars underlie this overall increase in spending. First, the market entry prices of innovator pharmaceutical products, or brand drugs and biologics, are at levels that some assessments consider unaffordable to the healthcare system. Second, prices for some established generic drugs such as digoxin and captopril have seen sharp and rapid increases. As an evidence-based patient advocacy organization dedicated to improving the cardiovascular health of all Americans, the American Heart Association has a unique role in advocating for treatments, including medicines that are available, affordable, and accessible to patients. This advisory serves to lay out a set of principles that will guide association engagement in pursuit of this goal.

show abstract

The American Heart Association’s 2008 Statement of Principles for Healthcare Reform

Cited by 51 publications

References 48 publications

Forecasting the Future of Stroke in the United States

Forecasting the Future of Stroke in the United States

Diagnostic performance of coronary computed tomography angiography versus exercise electrocardiography for coronary artery disease: a systematic review and meta-analysis

American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics

Contact Info

Product

Resources

About